Specializing in the synthesis of organic acids, ketoacids, and amino acids for pharmaceutical/materials research and metabolic analysis.
Early detection of cancer and bacterial infections saves lives; an emerging technology that enables rapid diagnoses of these conditions is called metabolic flux analysis. We have developed synthetic techniques that enable this technology by producing the necessary chemical reagents. These required molecules (13C-labelled metabolites) are highly specialized and challenging to produce, with some currently costing hundreds of dollars for an amount less than a grain of sand. Based on a decade of research experience and nearly a million dollars in research funding from agencies including NSF and NASA, we have developed the technology to directly replicate a fundamental biological pathway to these intermediates that avoids costly enzymes or fermentation. These techniques decrease the synthetic costs of the labelled metabolites by over an order of magnitude.
Contact us to find out more about aconabolics.
Frequently Asked Questions
Aconabolics specializes in the synthesis isotopically labeled organic acids, ketoacids, and amino acids for pharmaceutical/materials research and metabolic analysis. Our proprietary chemical reaction pathway enables the generation of both known and non-fermentable novel metabolites. Major products include isotopic and structural isomers of biochemical intermediates and analogs.
Meet our executive Team
Dr. Greg Springsteen, Ph.D., is a Henry Keith and Ellen Hard Townes Professor of Chemistry at Furman University. His work has been published in top international science journals and brought in over $750,000 in funding from NSF and NASA. He was named one of eight national Dreyfus Scholars in 2018.
Trent Stubbs is a rising senior majoring in biochemistry at Furman University. He is president of Furman’s chapter of the American Chemical Society, the founder of the Berea house service organization, and a Furman University Bell Tower Scholar,